He is determined to carry out several large billion kroner deals, but the task of finding two or three new billion kroner agreements seems to be drawing out.
The opportunities are few and far between and the valuations are at the high end of the scale.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.